BioNTech, UK collaborate on personalized mRNA cancer immunotherapy
BioNTech (NASDAQ:BNTX) Signed a tentative agreement with the UK government to provide up to 10 thousand patients with personalized mRNA cancer immunotherapies by 2030.
German COVID vaccine maker aims to provide personalized cancer therapies to these patients in clinical trials or treatments authorized under a Memorandum of Understanding (MoU).
BioNTech says the goal is part of a multi-year collaboration that focuses on three strategic areas: cancer immunotherapy based on mRNA or other drug classes, infectious disease vaccines and investments. in expanding BioNTech’s UK footprint as one of the company’s key markets.
According to the Memorandum of Understanding, the company and the UK government plan to accelerate the trial site and recruit patients for clinical candidates in BioNTech’s system for personalized mRNA cancer immunotherapy. and vaccines for infectious diseases.
The parties plan to use the UK’s clinical trials network, genomics and health data assets.
The company expects to be ready to take on its first patient with cancer in the second half of 2023.
BioNTech notes that it plans to invest in a UK Research and Development (R&D) center in Cambridge with an expected capacity of more than 70 scientists, who will first start R&D by the end of the year. first quarter of 2023.
In addition, the company said it will strengthen its UK footprint by setting up a regional headquarters in London to take on staff in global and regional support functions including regulation, healthcare. , intellectual property and legal.